Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

A Turning Point for ASML? UBS Upgrade Sparks Optimism for the Chip Sector Giant

Robert Sasse by Robert Sasse
September 5, 2025
in Analysis, European Markets, Semiconductors, Turnaround
0
ASML Stock
0
SHARES
189
VIEWS
Share on FacebookShare on Twitter

After navigating a challenging period, Dutch semiconductor equipment manufacturer ASML is showing signs of a potential recovery. In a notable shift, UBS has upgraded its rating on the company’s shares from “Neutral” to “Buy,” a move that follows a year where the stock declined by 20%. This bullish stance from the Swiss bank, which arrives amid lingering skepticism from other analysts, suggests the worst of the downturn may be over.

The upgrade is anchored on the belief that all known headwinds are now fully reflected in the share price. According to UBS analyst Francois-Xavier Bouvignies, concerns over weaker demand for lithography systems and ongoing uncertainties related to the Chinese market are already priced in.

UBS has set a new price target of 750 euros, a significant increase from its previous target of 660 euros. The bank’s forward-looking analysis is particularly striking, as it forecasts that ASML will achieve annual profit growth of 20 percent between 2026 and 2030. This projected acceleration is tied to imminent technological advancements in the chip industry.

Should investors sell immediately? Or is it worth buying ASML?

Two key developments are expected to be major catalysts. First, the new A14 processor node from TSMC is anticipated to drive renewed demand for ASML’s extreme ultraviolet (EUV) lithography systems. Second, the company’s groundbreaking next-generation High-NA EUV technology is on the verge of a commercial breakthrough. By the end of the decade, these advanced machines could contribute 15 to 20 percent of total company revenue, highlighting the immense growth potential for this monopolist in cutting-edge chip manufacturing.

However, this optimistic view is not universally shared. Other financial institutions have recently expressed caution. On September 2, Bank of America reduced its price target, citing macroeconomic uncertainties and potential tariff risks, with particular concern over sluggish demand from China. Similarly, both Erste Group and Freedom Broker have recently downgraded their ratings to “Hold.”

The upcoming quarterly report on October 15 is poised to be a critical test for these competing viewpoints. When ASML releases its third-quarter earnings, it will provide crucial insights into its current order book. While company management has thus far reaffirmed its full-year revenue guidance of 30 to 35 billion euros, investors are expected to scrutinize every detail of the report for clues about the company’s trajectory amidst conflicting market signals.

Ad

ASML Stock: Buy or Sell?! New ASML Analysis from February 7 delivers the answer:

The latest ASML figures speak for themselves: Urgent action needed for ASML investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

ASML: Buy or sell? Read more here...

Tags: ASML
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock
Analysis

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Next Post
AMD Stock

AMD's High-Stakes Balancing Act in the AI Boom

Apple Stock

Apple Stock Receives Major Boost from Court Victory and Emerging Market Surge

BioNTech Stock

BioNTech Achieves Major Oncology Breakthrough with Phase 3 Cancer Trial Success

Recommended

Dare Bioscience Stock

Dare Bioscience Stock: Analysts Project Triple-Digit Upside Potential

4 months ago
Bloom Energy Stock

Fuel Cell Leader Bloom Energy Capitalizes on AI Infrastructure Demand

3 months ago
AI travel

NextTrip Inc Announces Official Transition and Ticker Symbol Change

2 years ago
Genprex Stock

Genprex Shares Plunge Amid Heavy Selling Pressure

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

Trending

Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

by Jackson Burston
February 7, 2026
0

All eyes are on Camping World Holdings as it approaches a pivotal quarterly report. This will be...

Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com